Navigation Links
AIT Bioscience Taps Ligand Binding Assay Expert Dr. Ron Bowsher as Senior Research Advisor
Date:9/11/2012

INDIANAPOLIS, Sept. 12, 2012 /PRNewswire/ -- AIT Bioscience is pleased to announce that Dr. Ron Bowsher, an industry expert in bioanalysis of ligand binding assays, has partnered with the company as a senior research advisor bringing with him an impressive background in biotherapeutic drug research in both traditional pharmaceutical and the CRO industries.

"I am excited about my advisory role at AIT Bioscience, because I believe this organization is both highly innovative and customer-focused," said Dr. Bowsher, who has a long and illustrious history in biotherapeutic research and is a pioneer in regulated bioanalysis of macromolecules.

"The AIT Bioscience team is dedicated to providing both innovative and quality services as demonstrated by their cutting-edge use of electronic lab notebooks. I'm looking forward to helping them grow and expand their services for bioanalysis of large molecules, in order to help clients achieve expedited, quality data," he says.  In his role as senior research advisor of ligand binding assays, Dr. Bowsher will advise on technical, regulatory, and business development matters related to ligand binding methods.

"Dr. Bowsher is a pioneer in our industry and we are honored to have him as an advisor to our management team. His demonstrated leadership in ligand binding assays opens our services to a broader pipeline of molecules, allowing more clinical and non-clinical studies to benefit from our fully integrated electronic laboratory documentation system," said AIT Bioscience president Dr. Ron Shoup.

Dr. Bowsher brings more than 35 years experience in the pharmaceutical/biotech and contract research organization industries. He received a bachelor's degree in chemistry from Indiana University and holds a master's degree and doctorate in biochemistry from the Indiana University School of Medicine. He is an adjunct assistant professor of biochemistry and molecular biology at the IU School of Medicine. In addition to his new advisory role at AIT Bioscience, Dr. Bowsher maintains his robust consulting and laboratory businesses at B2S Consulting® (Indianapolis, IN), and B2S Labs (Shelbyville, IN), respectively.  Since 1980 he has published more than 100 research papers and monographs and 105 abstracts. He holds three patents. He is an AAPS Fellow and was awarded an AAPS Presidential Citation for his work on establishing an educational program for ligand binding assays.  In 2012, Dr. Bowsher received the Distinguished Alumnus Award, School of Science, Indiana University-Purdue University (IUPUI), Indianapolis IN.

About AIT Bioscience:

AIT Bioscience, LLC, headquartered in Indianapolis, Ind., is a bioanalytical contract research organization supporting pre-clinical and phase I-III clinical trials. AIT Bioscience provides robust analytical methods, automated sample logistics, with a systems-wide Quality by Design (QbD) operation that support programs through to the investigational new drug and new drug applications. AIT Bioscience has created a new standard for quantitative bioanalytical analysis and drug development in support of small biotech and large pharmaceutical companies. Learn more about AIT Bioscience at www.AITBioscience.com.


'/>"/>
SOURCE AIT Bioscience
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
2. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
3. Amarantus BioSciences to Present at the New York Biotechnology Association (NYBA) 21st Annual Meeting on May 2nd, 2012
4. Neurocrine Biosciences Reports First Quarter 2012 Results
5. Pressure BioSciences, Inc. to Discuss First Quarter 2012 Financial Results And Provide Business Update
6. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
7. Neurocrine Biosciences to Present at the Jefferies 2012 Global Healthcare Conference
8. HUYA Bioscience International Engages In Partnership With Zhuhai Sanzao Science and Technology Industrial Park
9. Tethys Bioscience and Lose it! Announce a Strategic Partnership to Support Diabetes Prevention
10. 3-V Biosciences To Present at the Seventh Annual JMP Securities Healthcare Conference
11. Sofie Biosciences receives $1M Phase II SBIR grant from the DOE
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 23, 2016 Research and Markets has ... Market Analysis 2016 - Forecast to 2022" report to ... report contains up to date financial data derived from varied ... major trends with potential impact on the market during the ... segmentation which comprises of sub markets, regional and country level ...
(Date:6/23/2016)... WAYNE, Pa. , June 23, 2016 ... provider, will launch its next generation clinical outcomes platform, Bracket ... DIA Meeting held on June 26 – 30, 2016 in ... 6.0, the first electronic Clinical Outcome Assessment product of its ... DIA Booth #715. Bracket eCOA 6.0 is a ...
(Date:6/23/2016)... June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations ... Latin America . ... ... ... ...
Breaking Medicine Technology:
(Date:6/25/2016)... Canada (PRWEB) , ... June 25, 2016 , ... Conventional ... pursuit of success. In terms of the latter, setting the bar too high can ... risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is ... associated with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of ...
(Date:6/24/2016)... MIAMI, Fla. (PRWEB) , ... June 24, 2016 , ... ... Florida Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this ... of Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this ...
(Date:6/24/2016)... ... ... makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair Minimum ... by 2020 and then adjusting it yearly to increase at the same rate as the ... wage floor does not erode again, and make future increases more predictable. , The company ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... proud to recognize Dr. Barry M. Weintraub as a prominent plastic surgeon and ... women in the world, and the most handsome men, look naturally attractive. Plastic ...
Breaking Medicine News(10 mins):